on the planning and execution of the Human Genome Project and has been elected to the board of directors of the American Society of Human Genetics. Dr. Duyk graduated from Wesleyan University in 1980 with a B.A. in biology and was elected to Phi Beta Kappa. He holds a Ph.D. and an M.D. from Case Western Reserve University and completed his medical and fellowship training at the University of California, San Francisco (UCSF). While at UCSF, he was a fellow of the Lucille P. Markey Foundation and was also awarded a postdoctoral fellowship from the Howard Hughes Medical Institute. Dr. Duyk currently serves on the boards of directors of Aerie Pharmaceuticals, Inc.; Alphabet Energy, Inc.; Amyris; Beta Renewables; DNAnexus, Inc.; Elevance Renewable Sciences, Inc.; Fourteen22, Inc.; Galleon Pharmaceuticals, Inc.; Genomatica; and Karos Pharmaceuticals, Inc., and is a board observer at Ultragenyx Pharmaceutical, Inc.
Pat Furlong, B.S.N., is the founding president and chief executive officer of Parent Project Muscular Dystrophy (PPMD), the largest nonprofit organization in the United States solely focused on Duchenne muscular dystrophy (Duchenne). The mission of PPMD is to end Duchenne. PPMD accelerates research, raises its voice in Washington, DC, demands optimal care for all young men, and educates the global community. Duchenne is the most common fatal genetic childhood disorder, which affects approximately 1 out of every 3,500 boys each year worldwide. It currently has no cure. When doctors diagnosed her two sons, Christopher and Patrick, with Duchenne in 1984, she did not accept “there’s no hope and little help” as an answer. She immersed herself in Duchenne, working to understand the pathology of the disorder, the extent of research investment, and the mechanisms for optimal care. Her sons lost their battle with Duchenne in their teenage years, but she continues to fight—in their honor and for all families affected by Duchenne. In 1994, Ms. Furlong, together with other parents of young men with Duchenne, founded PPMD to change the course of Duchenne and, ultimately, to find a cure. Today, she continues to lead the organization and is considered one of the foremost authorities on Duchenne in the world.
Daniel Geschwind, M.D., Ph.D., is the Gordon and Virginia MacDonald Distinguished Chair in Human Genetics and is a professor of neurology and psychiatry at the University of California, Los Angeles (UCLA), School of Medicine. He is director of the Neurogenetics Program and the Center for Autism Research and Treatment and co-director of the Center for Neurobehavioral Genetics at UCLA. Dr. Geschwind obtained an A.B. in psychology and chemistry at Dartmouth College and M.D. and Ph.D. degrees at Yale School of Medicine prior to completing his internship, residency (neurology), and postdoctoral fellowship at UCLA. He joined the UCLA faculty in 1997. His laboratory works to improve understanding of human